All lobbying filings

BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Lobbying for BREAKTHROUGH T1D (FORMERLY KNOWN AS JDRF INTL.)

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $220,000.00 expenses · posted Jul 20, 2026

Official filing document

Bills named in this filing 8

HR 8646
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
HR 9620
Military Next-Gen Collision Avoidance Act of 2026
S 4189
INSULIN Act of 2026
S 4612
SCREEN for Type 1 Diabetes Act of 2026
HR 9000
SCREEN for Type 1 Diabetes Act of 2026
HR 5467
PAAT Act
119-S-8270
Not yet in our database
HR 8018
ISLET Act

Lobbying activity 2

Budget/Appropriations

H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027; H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; Issues pertaining to NIH & FDA funding.

Health Issues

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.